NYXH Stock Overview
A medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Nyxoah S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €7.38 |
52 Week High | €17.60 |
52 Week Low | €3.79 |
Beta | 0.53 |
11 Month Change | -11.30% |
3 Month Change | -35.55% |
1 Year Change | 9.82% |
33 Year Change | -70.60% |
5 Year Change | n/a |
Change since IPO | -62.15% |
Recent News & Updates
It's Probably Less Likely That Nyxoah S.A.'s (EBR:NYXH) CEO Will See A Huge Pay Rise This Year
Jun 05Shareholder Returns
NYXH | BE Medical Equipment | BE Market | |
---|---|---|---|
7D | 12.2% | 0.5% | 0.9% |
1Y | 9.8% | 9.3% | 5.8% |
Return vs Industry: NYXH matched the Belgian Medical Equipment industry which returned 9.3% over the past year.
Return vs Market: NYXH exceeded the Belgian Market which returned 5.8% over the past year.
Price Volatility
NYXH volatility | |
---|---|
NYXH Average Weekly Movement | 11.3% |
Medical Equipment Industry Average Movement | 5.7% |
Market Average Movement | 3.5% |
10% most volatile stocks in BE Market | 6.1% |
10% least volatile stocks in BE Market | 2.5% |
Stable Share Price: NYXH's share price has been volatile over the past 3 months.
Volatility Over Time: NYXH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Belgian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 147 | Olivier Taelman | www.nyxoah.com |
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah S.A. Fundamentals Summary
NYXH fundamental statistics | |
---|---|
Market cap | €253.67m |
Earnings (TTM) | -€43.21m |
Revenue (TTM) | €5.13m |
49.5x
P/S Ratio-5.9x
P/E RatioIs NYXH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NYXH income statement (TTM) | |
---|---|
Revenue | €5.13m |
Cost of Revenue | €1.94m |
Gross Profit | €3.19m |
Other Expenses | €46.40m |
Earnings | -€43.21m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 06, 2024
Earnings per share (EPS) | -1.26 |
Gross Margin | 62.25% |
Net Profit Margin | -842.57% |
Debt/Equity Ratio | 10.3% |
How did NYXH perform over the long term?
See historical performance and comparison